As background, in 2017 Hikma entered into a settlement agreement with Jazz to sell an authorized generic of Xyrem^®.  Under the terms of this agreement, Hikma has a date certain launch of 1 January 2023, or earlier depending on certain market conditions, and 180 days exclusivity.

To align with Jazz’s updated expectations, Hikma now conservatively assumes it will launch its authorized generic on 1 January 2023 and that the revenue and profit contribution from the exclusivity period will shift to the first half of 2023. Reflecting this, Hikma is today updating guidance for its Generics business.

For 2022, Hikma now expects Generics revenue to be in the range of $710 million to $750 million and core operating margin to be around 20%, with the lower end of the range reflecting the possibility of further price erosion in the US generic market, should this materialize. This compares with Hikma’s previous guidance of Generics revenue growth in the range of 8% to 10% over full year 2021 revenue of $820 million and core operating margin in the range of 24% to 25%.

All other guidance remains unchanged.